Le Lézard
Classified in: Health
Subjects: PDT, EGV

RenalSense Obtains CE Mark for its Clarity RMStm Critical Care System for Real-time Monitoring of Urine Flow


JERUSALEM, Aug. 5, 2019 /PRNewswire/ -- RenalSense announced that it has obtained CE Mark approval for its Clarity RMStm system for real-time monitoring of urine flow in the critical care and peri-operative setting. The CE Mark approval allows RenalSense to commercialize its technology in the European Union (EU), where Fresenius Medical Care (Bad Homburg) is its distribution partner.

AKI occurs in over 55% of ICU patients, and is often associated with a high risk of chronic kidney disease, as well as increased morbidity and mortality. Clarity RMS, which facilitates early detection of changes in renal function and Acute Kidney Injury (AKI) risk, is installed in leading medical centers in the United States and Israel. The system continuously measures urine flow and automatically transmits real-time data, as well as notifications of fluctuations, on a 24/7 basis to enable rapid intervention, monitoring of treatment efficacy and fluid management.

"The CE Mark is a significant milestone for RenalSense, enabling our distribution partner, Fresenius Medical Care, to launch sales to European medical centers, where urine output will now be able to be monitored electronically in real-time, as is the standard practice for other vital signs in the OR and ICU," said Avi Kleiman, CEO.

In addition to obtaining the CE Mark approval, RenalSense also received ISO:13485:2016 certification for its quality management system.

RenalSense is a privately owned medical device company dedicated to real-time renal diagnostics. The company's first product, Clarity RMStm, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics. RenalSense's next generation products will provide additional real-time parameters and expanded diagnostic capabilities, to further improve critical care management in the ICU and peri-operative setting.

For more information please contact:
Jean-Paul Benhamou
VP Sales and Marketing, Global
Email: [email protected]
Website: http://www.renalsense.com

 

SOURCE RenalSense


These press releases may also interest you

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 07:00
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 at the 2024...

17 mai 2024
Family Braces, Calgary's largest group of orthodontists with five locations across the city, reports a strong start to the second quarter of 2024. This positive momentum builds on the group's successful first quarter, underlining its...

17 mai 2024
American Skin Association (ASA) announced the recipients of the 2024 Inaugural Founders Award and the 2024 Research Achievement Awards at the 2024 Society for Investigative Dermatology (SID) Annual Meeting. ...

17 mai 2024
The Honourable Seamus O'Regan Jr., Minister of Labour and Seniors, on behalf of the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Tom Osborne, Newfoundland and Labrador's Minister of Health and Community Services will make...



News published on and distributed by: